论文部分内容阅读
基因工程抗肿瘤导向药物是近年来通过基因工程产生的新一代抗肿瘤导向药物。通过对天然单克隆抗体在基因水平的改进,产生了低免疫原性的嵌合抗体和人源化抗体,以及小型化的单链抗体和单区抗体。由它们所制备的导向药物,不仅可减少或推迟导向治疗过程中的免疫反应,而且显示出有利于肿瘤导向治疗的药代动力学特征。一些具有独特生物学特性的受体分子和生长因子加入导向载体的行列,则给导向药物赋予了新的特点和意义。这些导向载体和DNA重组的“弹头”分子在基因水平偶联所产生的基因工程抗肿瘤导向药物正在给肿瘤治疗带来新的希望。
Genetic engineering anti-tumor-oriented drugs in recent years through genetic engineering to generate a new generation of anti-tumor-oriented drugs. By genetically improving natural monoclonal antibodies, chimeric and humanized antibodies with low immunogenicity, as well as miniaturized single chain antibodies and single-domain antibodies, are produced. Guiding drugs made by them not only reduce or delay the immune response during the course of the therapy, but also show the pharmacokinetic characteristics that are conducive to the tumor-oriented treatment. Some receptor molecules with unique biological characteristics and growth factors added to the ranks of the leading vector, then give the guiding drug with new characteristics and significance. Genetically-engineered antitumor-directed drugs produced by these targeting vectors and DNA-recombined “warhead” molecules coupled at the gene level are bringing new hope for cancer treatment.